 Pancreatic ductal adenocarcinoma, PDAC, is a highly aggressive cancer with a poor prognosis due to its resistance to conventional treatments such as chemotherapy and radiation. Recent advances in the field of neoadjuvant therapy, NAT, which involves administering pre-surgical treatments before surgery, have shown promise in improving patient outcomes. The goal of this review is to summarize the current knowledge about PDAC, discuss the potential benefits of NAT, and outline future research directions. This article was authored by Heng Chung-kong and Jeon Yu.